DK0857065T3 - Anvendelse af 2-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen til profylakse og behandling af følgerne efter aku - Google Patents

Anvendelse af 2-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen til profylakse og behandling af følgerne efter aku

Info

Publication number
DK0857065T3
DK0857065T3 DK96945354T DK96945354T DK0857065T3 DK 0857065 T3 DK0857065 T3 DK 0857065T3 DK 96945354 T DK96945354 T DK 96945354T DK 96945354 T DK96945354 T DK 96945354T DK 0857065 T3 DK0857065 T3 DK 0857065T3
Authority
DK
Denmark
Prior art keywords
ethoxycarbonylaminobenzene
fluorobenzylamino
acu
prophylaxis
consequences
Prior art date
Application number
DK96945354T
Other languages
Danish (da)
English (en)
Inventor
Angelika Rostock
Christine Tober
Chris Rundfeldt
Reni Bartsch
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Application granted granted Critical
Publication of DK0857065T3 publication Critical patent/DK0857065T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK96945354T 1995-10-26 1996-10-15 Anvendelse af 2-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen til profylakse og behandling af følgerne efter aku DK0857065T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19539861A DE19539861A1 (de) 1995-10-26 1995-10-26 Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
PCT/DE1996/001951 WO1997015300A2 (de) 1995-10-26 1996-10-15 Verwendung von 4-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen zur prophylaxe und behandlung der folgen der akuten und chronischen zerebralen minderdurchblutung sowie neurodegenerativer erkrankungen

Publications (1)

Publication Number Publication Date
DK0857065T3 true DK0857065T3 (da) 1999-10-18

Family

ID=7775835

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96945354T DK0857065T3 (da) 1995-10-26 1996-10-15 Anvendelse af 2-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen til profylakse og behandling af følgerne efter aku

Country Status (26)

Country Link
US (2) US5852053A (sk)
EP (1) EP0857065B1 (sk)
JP (2) JP4567101B2 (sk)
KR (1) KR100423823B1 (sk)
AR (1) AR004108A1 (sk)
AT (1) ATE178487T1 (sk)
AU (1) AU706735B2 (sk)
BR (1) BR9610899A (sk)
CA (1) CA2188841C (sk)
CZ (1) CZ291456B6 (sk)
DE (2) DE19539861A1 (sk)
DK (1) DK0857065T3 (sk)
ES (1) ES2131973T3 (sk)
GR (1) GR3030336T3 (sk)
HU (1) HU228014B1 (sk)
ID (1) ID16489A (sk)
IL (1) IL123523A (sk)
NO (1) NO316493B1 (sk)
NZ (1) NZ326754A (sk)
PL (1) PL185714B1 (sk)
RU (1) RU2201227C2 (sk)
SK (1) SK283222B6 (sk)
TW (1) TW457084B (sk)
UA (1) UA51681C2 (sk)
WO (1) WO1997015300A2 (sk)
ZA (1) ZA968991B (sk)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6472165B1 (en) * 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
AU2002338333A1 (en) * 2001-04-04 2002-10-21 Wyeth Methods for treating hyperactive gastric motility
US7205307B2 (en) * 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
PT1578740E (pt) * 2002-12-27 2007-05-31 Lundbeck & Co As H Derivados de 1, 2, 4-triaminobenzeno úteis para tratamento de distúrbios do sistema nervoso central
PL377221A1 (pl) * 2002-12-27 2006-01-23 H. Lundbeck A/S Pochodne 1,2,4-triaminobenzenu
MXPA05010174A (es) * 2003-04-25 2005-11-08 Lundbeck & Co As H Derivados de indol e indolina sustituidos.
US7799832B2 (en) 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
PL2298766T3 (pl) 2005-03-03 2014-09-30 H Lundbeck As Preparaty farmaceutyczne zawierające podstawione pochodne pirydyny
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
SG174095A1 (en) * 2006-08-23 2011-09-29 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
BRPI0719590A2 (pt) * 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
CA2731008A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
WO2013011518A1 (en) 2011-07-21 2013-01-24 Arch Pharmalabs Limited Process for the preparation of retigabine of the formula i and pharmaceutically acceptable salts thereof
CN103073455B (zh) * 2011-10-25 2015-08-19 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
CA3132310C (en) 2012-08-07 2024-01-09 Children's Medical Center Corporation Potassium channel openers for treating neurodegenerative diseases
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2817334B2 (ja) * 1990-03-29 1998-10-30 株式会社ツムラ 神経細胞保護剤
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
TW280819B (sk) * 1993-11-17 1996-07-11 Sumitomo Pharma
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen

Also Published As

Publication number Publication date
NO981503L (no) 1998-04-02
WO1997015300A2 (de) 1997-05-01
JPH11515007A (ja) 1999-12-21
SK52098A3 (en) 1998-09-09
CA2188841A1 (en) 1997-04-27
EP0857065B1 (de) 1999-04-07
JP2009007366A (ja) 2009-01-15
SK283222B6 (sk) 2003-03-04
PL325956A1 (en) 1998-08-17
BR9610899A (pt) 1999-07-13
CA2188841C (en) 2006-05-23
DE19539861A1 (de) 1997-04-30
IL123523A0 (en) 1998-10-30
EP0857065A2 (de) 1998-08-12
MX9803172A (es) 1998-09-30
US5852053A (en) 1998-12-22
NO981503D0 (no) 1998-04-02
HUP9900508A3 (en) 1999-11-29
NZ326754A (en) 2000-03-27
AU706735B2 (en) 1999-06-24
HUP9900508A2 (hu) 1999-06-28
TW457084B (en) 2001-10-01
ES2131973T3 (es) 1999-08-01
KR19990067021A (ko) 1999-08-16
AU1540097A (en) 1997-05-15
ID16489A (id) 1997-10-02
JP4567101B2 (ja) 2010-10-20
HU228014B1 (en) 2012-08-28
GR3030336T3 (en) 1999-09-30
AR004108A1 (es) 1998-09-30
RU2201227C2 (ru) 2003-03-27
US5849789A (en) 1998-12-15
KR100423823B1 (ko) 2004-08-25
CZ291456B6 (cs) 2003-03-12
CZ122598A3 (cs) 1998-09-16
IL123523A (en) 2001-12-23
NO316493B1 (no) 2004-02-02
ATE178487T1 (de) 1999-04-15
ZA968991B (en) 1997-06-10
UA51681C2 (uk) 2002-12-16
DE59601624D1 (de) 1999-05-12
WO1997015300A3 (de) 1997-07-03
PL185714B1 (pl) 2003-07-31

Similar Documents

Publication Publication Date Title
DK0857065T3 (da) Anvendelse af 2-amino-4-(4-fluorbenzylamino)-1-ethoxycarbonylaminobenzen til profylakse og behandling af følgerne efter aku
DK0881881T3 (da) Antiparasitært præparat til behandling og beskyttelse af kæledyr
DK1021410T3 (da) Prostaglandinagonister og deres anvendelse til behandling af knogletilstande
DK0791190T3 (da) Signaleringsgenstande og fremgangsmåde til fremstilling af samme
NO20002846L (no) Inhaleringsanordning og fremgangsmÕte ved samme
ID24320A (id) Turunan-turunan benzopiran tersubstitusi untuk pengobatan radang
DK0861081T3 (da) Anvendelse af epinastin til behandling af smerter
NO983284D0 (no) Antikoagolante midler egnet i behandling av trombose
DE69521107T2 (de) Ausrichtverfahren und Halbleiterbelichtungsverfahren
DK0841946T3 (da) Metoder til behandling af allergisk astma
MX9807473A (es) Procedimiento para la obtencion de aminas y aminonitrilos.
DK0815922T3 (da) Fremgangsmåde til afsvovling og decarbonisering
DK0831098T3 (da) Mellemprodukter og fremgangsmåde til fremstilling af olanzapin
DK91793A (da) Fremgangsmåde til overfladebehandling, midler til udøvelse og anvendelsen heraf
DE69417382T2 (de) Beschichtungsverfahren und Beschichtungsvorrichtung
DK0805797T3 (da) Fremgangsmåde til fremstilling af N-aryl- og N-hetarylhydroxylaminer
DK0898566T3 (da) Substituerede benzylaminer og anvendelse deraf til behandling af depression
NO973680D0 (no) Fremgangsmåte for fremstilling av ikke-vandige dispersjoner og deres anvendelse
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
DK0689437T3 (da) anvendelse af granisetron til behandling af post-operativ kvalme og opkastning
DK15997A (da) Indretning til opbevaring af tovværk og tilsvarende
DK0594528T3 (da) Fremgangsmåde og anlæg til behandling af halve slagtekroppe
DK0981349T3 (da) 5-alfa-pregnan-3-beta-ol-20-on-sulfat til behandling af tumorer og CNS sygdomme
DK1011678T3 (da) Anvendelse af mecamylamin til behandling af nikotin-responsive neuropsykiatriske lidelser
DK0979083T3 (da) Anvendelse af 1-ar(alk)yl-imidazolin-2-oner til behandling af angst- og stresstilstande